Core Viewpoint - New Century Healthcare (01518.HK) has issued a profit warning, expecting a loss attributable to shareholders between RMB 60 million and 70 million for the six months ending June 30, 2025, marking a significant decline from a net profit of RMB 25.2 million in the same period of 2024 [1][3]. Financial Performance - The company reported a revenue decline of 9.28% to RMB 846 million in 2024, with net profit plummeting by 43.71% to RMB 47.38 million, and a decrease in gross margin from 43.63% in 2023 to 40.75% [3]. - The shift from profit to loss in the first half of 2025 is attributed to reduced demand for pediatric and obstetric services, impairment losses on goodwill and other long-term assets, and the reversal of deferred tax assets [3]. Regulatory Issues - New Century Healthcare and several directors faced disciplinary action from the Hong Kong Stock Exchange due to violations related to connected transactions, resulting in a loss of over RMB 100 million [4]. - The Hong Kong Stock Exchange has mandated the company to conduct an independent internal review, and all involved directors are required to undergo training [4]. Company Overview - New Century Healthcare is a private medical group focused on providing high-quality medical services to children and women, with its first hospital established in 2002 and officially operating since 2006 [7].

将在京津、上海及大湾区扩大服务规模。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，3月14日，和睦家医疗宣布获华平投资增持股权，双方深化战略合作。 3月13日，复星医药（600196.SH）发布公告，其子公司复星实业拟以1.24亿美元现金对价向华平 投资旗下的Calcite Gem转让其所持有的标的公司940万股普通股，约占标的公司股份总数的 6.6%，交易对应的每股单价为13.2美元。标的公司主要资产系其通过控股子公司新风医疗集团NFH （下称"新风医疗"）持有及运营的和睦家医院和诊所。 本次交易完成后，华平投资将成为和睦家医疗的重要股东并获董事会席位 ，复星医药将彻底退出和 睦家医疗股东结构。此次合作升级彰显了华平投资对和睦家医疗发展战略的信心，将进一步帮助和睦 家医疗确立其在中国私立医疗产业中的领先地位。交易完成后，华平投资将成为和睦家医疗的重要股 东并获董事会席位。 华平投资合伙人、中国私募股权投资联席总裁方敏 表示："华平投资高度认可和睦家医疗所拥有的独 特优势以及过去几年所取得的成绩。我们很高兴此次增持和睦家医疗，未来也将继续支持公司发展， 力争用 ...